Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | recruiting | Phase 4 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 260 | PfizerINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07524322 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 63 |
| Regor Pharmaceuticals Inc.INDUSTRY |
| 1 |
| Jul 22, 2026 |
| clinicaltrials |
| NCT07591090 | A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | recruiting | Phase 2 | 200 | AkesoINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07718425 | EndoBreast Study - Assessment of Feasibility, Functional Outcomes, and Sensitivity of the Areola-Nipple Complex in Endoscopic Mastectomy(EndoBreast) | recruiting | — | 30 | Massimiliano BortoliniOTHER_GOV | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | recruiting | Phase 2 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04985058 | Real-world Data in Patients With Breast Cancer Treated With Abemaciclib(ENDURANCE) | recruiting | — | 108 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05297617 | Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk(LESS) | recruiting | Phase 2 | 696 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.(HEROES) | recruiting | Phase 2 | 170 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04230109 | Sacituzumab Govitecan In TNBC(NeoSTAR) | recruiting | Phase 2 | 239 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05464810 | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Early Phase 1 | 40 | Emory UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05535192 | TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients(THRIVE-65) | recruiting | N/A | 270 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)(PRESERVE) | recruiting | N/A | 171 | University Health Network, TorontoOTHER | 10 | Jul 17, 2026 | clinicaltrials |
| NCT06439771 | A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | recruiting | Phase 2 | 180 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06603597 | HER2-positive Breast Cancer Registry(PRO-HER2) | recruiting | — | 1,000 | Priyanka SharmaOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07055854 | Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors(MAC) | recruiting | Phase 1 | 60 | Oregon State UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07250204 | A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation. | recruiting | — | 60 | Hubei Cancer HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07661927 | Skipping Hormone Therapy in Low-Risk Early Breast Cancer(NoELA) | recruiting | Phase 2 | 700 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02290834 | Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer | recruiting | N/A | 200 | Massachusetts General HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05350722 | Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients(ABLATIVE-2) | recruiting | N/A | 100 | Amsterdam UMC, location VUmcOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT05667532 | The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts | recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06452485 | Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer(RT-HYPE) | recruiting | — | 500 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06555068 | A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 528 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06640881 | Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial(REPEAT) | recruiting | Phase 2 | 25 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07264985 | Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib | recruiting | — | 60 | Hubei Cancer HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708194 | Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | recruiting | Phase 1 / Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05996107 | Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer | recruiting | Phase 1 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07182721 | SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment(SHINE-HER) | recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07258563 | The TASTY-steering Study(TASTY-steering) | recruiting | N/A | 201 | University Medical Center GroningenOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | recruiting | — | 30 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04494945 | Identifying and Caring for Individuals With Inherited Cancer Syndrome | recruiting | N/A | 27,500 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06433609 | Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | recruiting | Phase 2 | 113 | Beijing GoBroad HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06896162 | PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival(PROGRESS) | recruiting | N/A | 500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06964906 | Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer(NeoHunter) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06966388 | Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation | recruiting | Phase 1 | 33 | Virginia Commonwealth UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702708 | Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer | recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703033 | Multicenter Cardiac Decision Impact Study in People With Breast Cancer(CarDI) | recruiting | N/A | 1,000 | UMC UtrechtOTHER | 4 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05142800 | Screening For BCRL In Targeted Therapy For Breast Cancer | recruiting | — | 261 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06037954 | A Study of Mental Health Care in People With Cancer | recruiting | N/A | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06970912 | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer(DNADalHR) | recruiting | Phase 2 | 393 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06976944 | Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer(PRELUDE) | recruiting | Phase 2 | 24 | Yukinori OzakiOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07117630 | An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07238894 | A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients | recruiting | N/A | 200 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07243002 | Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.(REPOWER) | recruiting | — | 3,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 22, 2026source: clinicaltrials